Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NaliCap vs NAPOLI in Gemcitabine-pretreated Pancreatic Cancer
NCT04371224Phase 2Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2020
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Progression-Free Survival at 12 months. Started Jun 2020; status: recruiting.
02
Drugs
capecitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04371224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04371224.